VERAXA Biotech (NASDAQ: VRXA) announced on July 23, 2026, that it has received Scientific Advice from Germany’s Paul-Ehrlich-Institute (PEI) for its lead BiTAC®-TCE program. The regulatory feedback supports the company’s proposed development strategy, including biological rationale, safety assessments, and non-clinical development plan, providing early guidance before advancing toward clinical studies.
The Scientific Advice procedure allows drug developers to consult with regulatory experts before clinical trials begin, helping align development strategies with regulatory expectations. VERAXA believes this advice reduces development uncertainty by providing greater clarity on the path forward. The company’s lead BiTAC®-TCE candidate previously generated encouraging preclinical data presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting.
VERAXA continues to build a diversified oncology pipeline that includes bispecific T-cell engagers, antibody-drug conjugates (ADCs), and other engineered antibody formats. The latest regulatory milestone follows continued progress in manufacturing and development as the company advances next-generation antibody therapeutics for cancer.
For more information, see the full announcement at https://ibn.fm/zBiDU. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
Forward-looking statements: Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth under "Risk Factors" in the Company's most recent Annual Report on Form 10-K or updates in subsequent filings with the SEC. Undue reliance should not be placed on these forward-looking statements, and the company undertakes no duty to update this information unless required by law.
